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    INTRODUCTION 
Colorectal cancer is the third most common cancer worldwide, with an estimated 
130,000 new patients diagnosed each year. It is the second leading cause of death because 
of cancer (approximately 55,000 people annually)[1]. In India the incidence of colorectal 
cancer is 3.9 per one lakh population and the mortality rate is 2.8 per one lakh 
population[2]. About 60% of all patients diagnosed with colorectal carcinoma will present 
with locally advanced disease[3]. Appropriate therapeutic decision making for these 
individuals depends primarily on the depth of penetration of the primary tumor and 
metastatic disease in  the regional lymph nodes[3].  
NORMAL LARGE BOWEL 
The large bowel comprises the terminal 1 to 1.5 meters of the gastrointestinal tract 
and is divided into caecum, ascending colon, transverse colon, descending colon, sigmoid 
colon & rectum. 
HISTOLOGY 
The large bowel wall is composed of four layers  
1. Mucosa 
Epithelium   
Lamina propria 
Muscularis mucosa 
2. Sub mucosa 
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3. Muscularis propria 
4. Serosa  
The mucosa is lined by columnar epithelium into which the crypts open. The 
surface epithelium is composed of absorptive cells and goblet cells. In addition the 
surface epithelium contains immature and undifferentiated cells, endocrine cells and 
paneth cells. The epithelium overlying the lymphoid follicles of lamina propria contains 
follicle associated epithelial cells or ‘M’ cells (M for microfold or membrane cells).   
The absorptive cells have basally located nuclei, mucin negative acidophilic 
cytoplasm and luminally directed apical striated borders. They absorb excess water and 
electrolytes from the intestinal contents. The goblet cells synthesize, store and secrete 
mucin granules. The paneth cells are seen only in caecum and proximal right colon and 
they secrete lysozyme and epidermal growth factor. Lymphocytes and occasional 
eosinophils may be present between the surface epithelial cells. The crypts are tubular 
and are arranged parallel to each other. 
The lamina propria contains few lymphocytes (both T and B cells), plasma cells, 
histiocytes and mast cells scattered in a network of collagen fibers, smooth muscle 
bundles, vessels and nerves. Lymphoglandular complexes are normal structures formed 
by deep crypt epithelium surrounded by lymphoid follicles which extend from mucosa to 
submucosa. Pericryptal fibroblast sheath is a collection of fibroblasts and myofibroblasts 
located around the crypts in superficial lamina propria. 
The muscularis mucosa is composed of thin layer of smooth muscles. The 
submucosa is composed of loose connective tissue similar to that of lamina propria. It 
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also contains submucosal plexus of Meissner and often contains fat cells. The muscularis 
propria is composed of inner circular and outer longitudinal layers of smooth muscles 
with the myenteric plexus of Auerbach between them. The outer layer is collected to 
form three thick bands known as taenia coli. The taenia is shorter in length than the other 
layers of the colonic wall. This results in the production of sacculations or haustrations on 
the wall of the colon.     
The serosa is composed of a single layer of flattened to cuboidal mesothelial cells 
and the subjacent fibroelastic tissue. It forms small pouches filled with fat known as 
appendices epiploicae. The serosa is missing over the posterior aspect of ascending and 
descending colon.  
THE VERMIFORM APPENDIX 
The appendix is the narrowest part of the gut. The crypts are poorly formed. The 
longitudinal muscle coat is complete and thick all around. Taenia coli are absent. The 
submucosa contains abundant lymphoid tissue that may completely fill it. The lymphoid 
tissue is not present at birth, it gradually increases and it is best seen in children above 10 
years of age. Subsequently there is progressive reduction in quantity of lymphoid tissue. 
THE RECTUM 
The rectum has a continuous coat of longitudinal muscle and there is no taenia 
coli. The peritoneum covers the front and sides of the upper one-third and only the front 
of the middle third. The rest of the rectum is devoid of a serous covering.  
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WHO CLASSIFICATION OF PRIMARY TUMOURS OF COLON AND 
RECTUM [4] 
Tumours of the colorectal region are classified  pathologically into different types 
which are based on the microscopic features. 
 
 
 Epithelial tumours  
 
Non-epithelial tumours  
 
I. Adenoma 
a. Tubular 
b. Villous 
c. Tubulovillous 
d. Serrated 
 
II. Intraepithelial neoplasia 
a. Low grade 
b. High grade 
III. Carcinoma 
a. Adenocarcinoma 
b. Mucinous carcinoma 
 
I. Lipoma 
II. Leiomyoma 
III. Gastrointestinal stromal tumour 
IV. Leiomyosarcoma 
V. Angiosarcoma 
VI. Kaposi sarcoma 
VII. Malignant melanoma 
VIII. Malignant lymphoma 
IX. Marginal zone lymphoma 
X. Mantle cell lymphoma 
XI. Diffuse large B cell lymphoma 
XII. Burkitt lymphoma  
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ADENOCARCINOMA 
Adenocarcinoma is the most common tumour type. Most are well to moderately 
differentiated and lack specific histological features, although colorectal tumours tend to 
show cribriform patterns with central necrosis, a feature that is useful if a metastatic 
tumour is encountered with an occult colorectal primary. Dysplasia in adjacent mucosa 
may be seen, but frequently the invasive tumour obliterates any pre-existing polyp from 
which it may have arisen[5]. 
 
 
c. Signet ring cell carcinoma 
d. Small cell carcinoma 
e. Squamous cell carcinoma 
f. Adenosquamous carcinoma 
g. Medullary carcinoma 
h. Undifferentiated carcinoma 
IV. Carcinoid  
a. Enterochromaffin cell 
b. L cell 
c. Others 
            V.      Mixed carcinoid - adenocarcinoma  
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MUCINOUS ADENOCARCINOMA 
This is one of the subtypes of adenocarcinoma that secretes extracellular mucin. 
At least 50% of the tumour must be mucinous in order to make this diagnosis. Mucinous 
adenocarcinomas are associated with microsatellite instability. Whether mucinous 
tumours have a better prognosis is uncertain. Mucinous change may also be seen in 
conventional adenocarcinomas treated with neoadjuvant chemoradiotherapy[6]. 
SIGNET RING CELL CARCINOMA 
Signet ring cell carcinoma is composed of at least 50% cells with intracytoplasmic 
mucin and eccentrically placed nuclei, resembling gastric signet ring cell tumours. The 
tumour grows in a diffuse fashion[7]. 
SMALL CELL CARCINOMA 
Small cell carcinoma may have areas of glandular or squamous differentiation. 
The prognosis is extremely poor[8]. 
SQUAMOUS AND ADENOSQUAMOUS CARCINOMAS 
These are extremely rare tumours. They have been associated with ulcerative colitis, 
schistosomiasis and pelvic irradiation. The survival rates are similar to adenocarcinomas. 
The following criteria is essential for making the diagnosis of squamous or 
adenosquamous carcinomas 
§ There must be no other sites of squamous cell carcinoma in the body 
§ There must be no involvement of cloacogenic or squamous lined mucosa[9]. 
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MEDULLARY CARCINOMA 
This is an important subtype of colorectal cancer, added to the WHO 
classification in 2000. It has a characteristic phenotype with sheets of cells and numerous 
tumour infiltrating lymphocytes on microscopy. This phenotype is associated with the 
Lynch cancer family syndrome (Hereditary Non-Polyposis Colorectal Cancer). Patients 
with this syndrome may also have ovarian, endometrial, skin and other gastrointestinal 
tumours. The colorectal tumours show a loss of mismatch repair proteins such as MSH 
(MutS, Escherichia coli, Homolog in 60% of cases) or MLH (MutL, Escherichia coli, 
Homolog in 30% of cases), which can be demonstrated with immunohistochemistry[10]. 
UNDIFFERENTIATED CARCINOMA 
They represent less than 1% of colorectal cancers. They are malignant epithelial 
tumours that have no glandular or other features to indicate definite differentiation. The 
absence of intracytoplasmic mucin helps to differentiate these tumours from poorly 
differentiated adenocarcinomas[11]. 
CARCINOIDS AND NEUROENDOCRINE CARCINOMA 
They are rare in the colon but focal neuroendocrine differentiation can occur in 
conventional adenocarcinomas. These are commonly seen in caecum and rectum[12]. 
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MIXED CARCINOID - ADENOCARCINOMA  
They originate from the endodermally derived multipotential cells located at the 
base of the crypts which during the neoplastic transformation undergo differentiation 
along several different pathways[13]. 
MESENCHYMAL TUMOURS 
Mesenchymal tumors in the colorectum are rare. Histologically they resemble 
their counterparts in soft tissues. Leiomyoma is the commonest mesenchymal tumour[14]. 
LYMPHOMA 
Lymphomas are less frequent in large bowel. They are nearly always of non-
Hodgkin’s type. Most of them belong to MALT-type (Mucosa Associated Lymphoid 
Tissue) category[15]. 
METASTATIC TUMOURS 
Metastases form disc like areas with central ulceration. They originate from 
malignant melanoma, lung tumours, renal cell carcinoma or mesothelioma.[16]             
Colorectal adenocarcinomas affect males slightly more than females and the mean 
age of incidence is 62 years. Both environmental and genetic factors are involved in the 
cause and pathogenesis. 
There are a number of genetic mutations involved in colorectal carcinogenesis. 
These can be assessed by immunohistochemistry.  Mutations in p53 have been found to 
   9 
 
occur in 70% to 80% of patients with colon cancer[1]. This p53 mutation was proposed as 
a late event in the transition from adenoma to carcinoma.  
Preclinical investigations have demonstrated that mutant p53 renders malignant 
cells less sensitive to most chemotherapeutic agents, with the exception of the taxanes, 
which seem to be indifferent to p53 status. The purpose of this study is to analyse the age, 
sex and site distribution in colorectal adenocarcinomas in our institution and to 
investigate the level of expression of P53 in colorectal adenocarcinomas and correlate 
this with the histological grade and stage. 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
1. To analyse age and sex distribution of colorectal adenocarcinomas   
2. To analyse site of distribution of colorectal adenocarcinomas 
3. To assess the level of expression of p53 in colorectal adenocarcinomas. 
4. To correlate the level of expression of p53 with the grade and stage of colorectal 
adenocarcinomas 
 
 
 
 
 
 
 
    
 
 
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 Colorectal carcinoma is a major cause of mortality and morbidity worldwide. 
Colorectal adenocarcinoma accounts for over 90% of the malignant tumors of the large 
bowel [17]. Incidence rates of colorectal cancer are increasing in many countries. 
Unfortunately, despite improvements in medical and surgical provision, there has been 
comparatively little change in mortality from colorectal cancer during the past 40 years 
and the overall five year survival is only around 40% [18]. 
The cause and pathogenesis of colorectal adenocarcinoma are related to both 
environmental and genetic factors, the former are largely dietary. The factors most 
closely associated with increased colorectal cancer rates include low intake of 
unabsorbable vegetable fibers and high intake of refined carbohydrates and fat. The 
reduced fiber content leads to decreased stool bulk and altered composition of intestinal 
microbial flora. This change may increase the synthesis of toxic oxidative by-products of 
bacterial metabolism which act as carcinogens[1].  
Deficiency of vitamin A C, E which act as anti-oxidants & high fat intake which 
enhances the hepatic synthesis of cholesterol and bile acids that are converted into 
carcinogens by intestinal bacteria are also implicated as risk factors for colorectal 
carcinomas[1,19]. The genetic factors include mutations of APC (Adenomatous Polyposis 
Coli), K-RAS, p53, and mismatch repair genes[1,20]. 
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STAGING OF COLORECTAL ADENOCARCINOMAS 
Staging of colorectal cancer is an estimate of the amount of penetration of the 
tumour. It is performed for diagnostic and research purposes and to determine the best 
method of treatment. The systems for the staging of colorectal cancers depend on the 
extent of local invasion, the degree of lymph node involvement and whether there is 
distant metastasis.  
Definitive staging can only be done after surgery has been performed and 
pathology reports are reviewed. An exception to this principle would be after a 
colonoscopic polypectomy of a malignant pedunculated polyp with minimal invasion. 
Preoperative staging of rectal cancers may be done with endoscopic ultrasound. 
Additional investigations which are useful in detecting metastases include abdominal 
ultrasound, CT, PET scanning and other imaging studies. 
The most common and most widely used staging system is the TNM (for 
tumors/nodes/metastases) system, from the American Joint Committee on Cancer 
(AJCC). The TNM system assigns a number based on three categories. "T" denotes the 
degree of invasion of the intestinal wall, "N" the number of lymph node involvement, and 
"M" the presence or absence of metastases. The broader stage of a cancer is usually 
quoted as number I, II, III, IV derived from the TNM value grouped by prognosis, a 
higher number indicates a more advanced cancer and likely a worse outcome. Details of 
this system are in the table below: 
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AJCC TNM STAGE TNM stage criteria for colorectal cancer[21] 
Stage 0 Tis N0 M0 Tis: Tumor confined to mucosa; cancer-in-situ  
Stage I T1 N0 M0 T1:  Tumor invades submucosa 
 T2 N0 M0 T2:  Tumor invades Muscularis propria 
Stage II-A T3 N0 M0 
T3:  Tumor invades subserosa or beyond (without 
other organs involved) 
Stage II-B T4 N0 M0 
T4:  Tumor invades adjacent organs or perforates 
the visceral peritoneum 
Stage III-A T1-2 N1 M0 N1:  Metastasis to 1 to 3 regional lymph nodes.  
Stage III-B T3-4 N1 M0 N1:  Metastasis to 1 to 3 regional lymph nodes.  
Stage III-C any T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes.  
Stage IV any T, any N,    M1 M1: Distant metastases present.  
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DUKE’S SYSTEM [22] 
Duke’s classification is an older and less complicated staging system that predates 
the TNM system. It identifies the stages as: 
§ A - Tumour confined to the intestinal wall 
§ B - Tumour invading through the intestinal wall 
§ C - With lymph node(s) involvement (this is further subdivided into C1 where 
only the regional nodes are involved and C2 where the nodes at the point of 
mesenteric blood vessel ligature are involved) 
§ D - With distant metastasis 
A few cancer centers still use this staging system. 
ASTLER-COLLER STAGING SYSTEM[22] 
§ A:   Tumor limited to the mucosa  
§ B1: Tumor involving the muscularis externa but not penetrating it  
§ B2: Tumor penetrating through the muscularis externa  
§ C1: Tumor confined to the bowel wall with regional lymph node 
metastases  
§ C2: Tumor penetrating through the wall with regional lymph node 
metastases 
§ D: Distant metastases. 
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Additional Staging: 
v Venous invasion (V) 
§ V0 : No venous invasion 
§ V1 :  Microscopic venous invasion 
§ V2  : Macroscopic venous invasion 
v Lymphatic invasion (L) 
§ L0 : No lymphatic vessel invasion 
§ L1 : Lymphatic vessel invasion. 
J. Walker et al[23], calculated 5 year survival rates in colorectal carcinoma patients 
who underwent surgery followed by chemotherapy or radiotherapy and correlated with 
the stage of the disease. He concluded in his study that histopathological staging is at 
present the most accurate prognostic factor for survival and recurrence. 
HISTOPATHOLOGICAL GRADING OF COLORECTAL 
ADENOCARCINOMAS [24]  
Histological grade describes how closely the tumor cells resemble normal cells. In 
general, the grading of colorectal carcinoma is based on architectural features, as well as 
cytological features (e.g., pleomorphism and hyperchromatism). However, the degree of 
gland formation is widely regarded as the most important feature in grading. There are 
three grades in colorectal adenocarcinomas:  
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§ Grade 1: Also called well differentiated. The tumour is composed mainly of 
simple tubules or glands in which nuclear polarity is easily discerned and the 
nuclei are of uniform size.  
§ Grade 2: Also called moderately differentiated. The tumour is composed of 
tubules that may be simple, complex or slightly irregular in which nuclear polarity 
is barely discernible or is lost.  
§ Grade 3: Also called poorly differentiated. The tumour is predominantly 
composed of solid pattern and there is loss of nuclear polarity. 
P53[25] 
 P53 is a tumor suppressor gene that is located on chromosome 17p13. It is the 
single most common target for genetic alteration in human tumors. The product of p53 
gene is a phosphoprotein that is activated by DNA damage and involved in the process to 
determine whether the cells should stop replication or die by apoptosis. In total p53 
targets around 150 genes to prevent proliferation of damaged cells. As such p53 has been 
described as “the guardian of the genome”, the "guardian angel gene", and the "master 
watchman", referring to its role in conserving stability by preventing genome mutation. 
 The p53 tumour suppressor gene is mutated in approximately 70 to 80% of 
colorectal cancer[1,25]. Mutation or loss of p53 usually occurs at the time of the transition 
from adenoma to carcinoma in the adenoma-carcinoma sequence. The frequency of p53 
abnormalities increases with the progression of the lesion. The protein product of p53 
gene induces G1 cell-cycle arrest to facilitate DNA repair during replication of cells 
exposed to environmental or oncogenic stress. 
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When DNA damage is too great to be repaired, it can induce apoptosis and this is 
considered a major pathway whereby p53 exerts its tumour suppressor function. Mutation 
of the p53 tumor suppressor gene is thought to play an important role in the progression 
of colorectal cancer and might therefore represent a clinically useful marker of prognosis.        
           Despite 20 years of investigation, the impact of p53 mutation on clinical outcome 
is far from being conclusive. Prognostication of newly diagnosed colorectal cancer 
(CRC) predominantly relies on stage as defined by the  American Joint Committee on 
Cancer classification. The 5-year survival rate for patients with CRC is largely dependent 
on TNM stage[26]. The TNM staging system was initially developed to predict prognosis, 
but its function has expanded to aid in the choice of treatment and in the selection of 
patients for clinical trials[26].  
Tumour extent, lymph node status, tumour grade and the assessment of lymphatic 
and venous invasion are still the most important morphological prognostic factors. 
Evidence suggests that tumour budding and tumour border configuration are important 
additional histological parameters but are not regarded as essential in prognosis. 
Although several molecular features, such as LOH18q and p53 mutation analysis have 
shown promising results in terms of their prognostic value, the American Society of 
Clinical Oncology Tumor Markers Expert Panel does not currently recommend their use 
in routine practice[26]. 
Immunohistochemical markers currently being investigated for their prognostic 
impact include proteins involved in the wide array of signaling pathways mediating 
colorectal tumour progression and metastasis. 
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The WNT signaling pathway involving beta-catenin,[27,28] APC gene[28] & E-
cadherin[28,29],  the transforming growth factor-(TGF)-beta pathway,[30] the TGF beta 
receptors TGFbRI, TGFb RII,[31,32] the RAS signaling pathway involving, among the 
novel potential markers, Raf-1 kinase inhibitor protein (RKIP) [33,34,35] and the receptor 
for hyaluronic acid mediated motility (RHAMM)[36] are examples of potential targets for 
immunohistochemical prognostic studies.  
Markers of cell cycle arrest (p21, p27, p53[37,38,39]), apoptosis (Bcl-2[40], Bax[41], 
apoptosis protease activating factor (APAF)-1[42]), proliferation (Ki67[43]) and DNA 
repair (thymidylate synthase, TS[43]) have also been explored for their prognostic value. 
Martin Kruschewski et al[44], studied colorectal adenocarcinomas & the p53 
immunohistochemical staining was scored based  on the percentage of positive tumour 
cells as follows: 
 
 
 
 
 
 
 
 
SCORE 
 
% OF POSITIVE TUMOUR CELLS  
 
0 
 
1 
 
2 
 
3 
 
 
0% 
 
1% - 10% 
 
11% - 25% 
 
>25% 
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Antonio Russo et al[45] in his study, which involved a total of 3,583 CRC patients 
from 25 different research groups in 17 countries, found that the overall frequency of p53 
mutation in this CRC series was 42%. 34% of the proximal colon tumours and 45% of 
the distal colon and rectal tumours had p53 mutations. They were associated with 
lymphatic invasion in proximal tumours. In distal colon tumours, deletions causing loss 
of amino acids were associated with worse survival. For proximal colon tumours, only 
p53 mutations in exon 5 were significantly associated with worse survival.  In this group, 
worse outcome compared with tumours with  wild-type p53 was observed for denaturing 
mutations, multiple mutations, or mutations yielding the same amino acid side group or 
an amino acid loss. For rectal tumours, only those giving rise to an amino acid loss were 
significantly associated with worse survival. 
A.Conlin et al[46] studied a series of 107 in-patients treated surgically for 
colorectal cancer and found that patients with K-ras mutations had significantly poorer 
overall survival than patients without K-ras mutations. K-ras mutations were also 
significantly associated with poorer disease specific survival. The presence of APC and 
p53 mutations did not affect survival in this cohort of patients. 
Yamaguchi et al[47] studied p53 immunoreactivity in 100 patients with colorectal 
adenocarcinoma using immunohistochemistry by the use of a monoclonal antibody with a 
follow-up of up to 4 years. The author found that the immunoreactivity was found in 61% 
of specimens from 100 patients with colorectal cancer. The pattern of p53 expression was 
mainly detected in the nuclei of the cancer cells. There was no significant correlation 
between the expression of p53 and the histologic grade, tumour size, serosal invasion, 
lymphatic invasion, venous invasion, lymph node metastasis, or liver metastasis. 
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However, patients with p53-positive tumours had a greater relative risk of death 
compared with those with p53-negative tumours. The p53-negative tumours showed a 
recurrence rate of 5.9%. For the p53 positive-tumours, a recurrence rate of 23.8% was 
recorded. With these results the author concluded that the immunoreactivity of p53 may 
be a biologic marker of prognostic significance. Similar results have been obtained using 
direct sequencing to detect p53 mutation. 
Sun et al[48] studied the prognostic significance in 293 colorectal adenocarcinoma 
patients using p53 expression in relation to DNA ploidy. The author found that the 
nuclear p53 expression showed no relation with survival or Dukes' stage of the tumour. 
However, the frequency of cytoplasmic expression increased with advancing Dukes' 
stage and cytoplasmic expression was associated with poor survival. Among tumours of 
Dukes' stage A to C, cytoplasmic expression showed prognostic value independent of 
nuclear staining, grade of the tumour, and Dukes' stage. The author concluded that 
cytoplasmic expression of p53 may be a useful biological indicator of prognosis in 
colorectal adenocarcinoma. Subsequent analysis conducted in the same patient cohort 
after a longer follow-up period concluded that positivity for both nuclear and cytoplasmic 
p53 was associated with the poorest survival. 
Zhang et al[49] studied p53 immunoreactivity in 293 patients by 
immunohistochemistry using CM1, PAb1801, DO7, and DO1 antibodies on paraffin-
embedded colorectal adenocarcinomas. The author found that p53-positive staining by 
any of the antibodies predicted significantly poor prognosis compared with p53-negative 
reactivity. These results suggest that there was essentially no difference in the 
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significance of p53 overexpression as detected by any of the four antibodies with regard 
to clinicopathological variables. 
Soong et al[50] studied  p53 mutation and expression by both IHC and by 
polymerase chain reaction single-strand conformational polymorphism (SSCP) 
respectively which showed accumulation of p53 protein to be associated with improved 
survival, independent of tumour stage and grade. Mutation of the p53 gene was also 
associated with a trend towards improved survival, particularly in distal colorectal 
tumours. 
Hamelin et al[51] performed a study which included 85 colorectal carcinomas for 
mutations in exons 5-8 of this gene. A strong correlation between the presence of a 
mutation and short survival was observed when tumours were classified according to 
their histological stage. A multivariate Cox model analysis showed that p53 mutation, 
rather than 17p allelic loss (previously proposed to convey prognostic information), was 
retained as the only independent prognostic factor. 
Soong et al[52] studied the prognostic significance of p53 gene mutation and 
influence of tumour site, stage, adjuvant chemotherapy and type of mutation in  995 
Dukes' B and C CRC patients, the majority of whom did not receive chemotherapy. The 
author found that p53 gene mutation had no prognostic value in the overall series or in 
different site or stage subgroups. None of the different types of p53 gene mutation 
showed prognostic value. A trend for association with worse survival was observed in the 
patient subgroup that received adjuvant chemotherapy. 
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Flamini et al[53] studied prognostic significance of p53 overexpression by 
immunohistochemistry in 96 consecutive colorectal cancer patients. The author found 
that forty-seven per cent of the cases were p53 positive, a statistically significant 
correlation being found with Dukes’ stage. In his study advanced Dukes’ stage tumours 
were localized in the right colon, where a higher percentage of p53 positivity (67% 
versus 40% of the left side), as well as a higher frequency of cytoplasmic staining was 
observed. The author concluded from the data obtained that there is a strong correlation 
between p53 nuclear staining and prognosis.  
Yuan-Tzu Lan et al[54] studied the value of p53 protein accumulation as a 
prognostic marker in 258 patients who received surgical treatment for colorectal cancer. 
The author evaluated p53 expression in tumour tissue by immunohistochemical analysis 
using the human p53-specific mouse monoclonal antibody, PAb1801. He found that 97 
cases (37.6%) had overexpression of p53 in tumour tissues. The accumulation of p53 
protein in tumour tissues did not correlate with age, gender, preoperative serum 
carcinoembryonic antigen (CEA) level, mucin content, nodal status, and tumour stage. A 
statistically significant correlation was found between p53 overexpression and location of 
the tumor in the rectum. Well to moderately differentiated tumours had significantly 
higher frequency of p53 overexpression than poorly differentiated tumors (60 vs. 40%). 
The author concluded that the accumulation of p53 protein might have a favorable 
prognostic value in colorectal cancer. 
Bouzourene et al[55] has evaluated p53 and K-ras as prognostic factors for Dukes' 
stage B colorectal cancer in a clinically and therapeutically homogeneous group of 122 
sporadic Dukes' B colorectal carcinomas with a median follow-up of 67 months. On 
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paraffin embedded tissue p53 staining was performed by immunohistochemistry using 
the monoclonal antibody DO7. Mutations in exons 5-8 of the p53 gene were assayed in 
paraffin -embedded tissue by the single-strand conformation polymorphism (SSCP) 
assay. Nuclear p53 staining was found in 57 (47%) tumours. Aberrant migration patterns 
indicating mutation of the p53 gene were found in 39 (32%) tumours. The author 
concluded that assessment of p53 protein expression is more discriminative than p53 
mutation to predict the outcome of Dukes' stage B tumours. 
Heide et al[56] analysed 33 liver metastases of colorectal carcinomas and 19 
primary colon carcinomas from the same hospital with respect to mutational changes, 
loss of heterozygosity and expression of the p53 tumour suppressor gene. Direct 
sequencing of PCR products corresponding to the coding region of p53 revealed that 13 
of 19 primary tumours (68%) and 23 of 33 liver metastases (70%) had mutations in the 
p53 gene. The distribution of mutations along the coding region of p53 was similar in 
liver metastases as compared to the primary tumours. Thus, codon specificity did not 
seem to be a relevant factor and cells carrying specific p53 mutations seem to have no 
selective advantage in the metastasizing process. Comparing this data with the mutational 
spectra found in other countries did not reveal differences in the distribution of mutations 
along the coding region. Most of the metastases analyzed showed loss of heterozygosity 
(LOH, 9 of 12 cases, 75%) and strong nuclear staining in immunohistochemistry (10 of 
17 cases, 59%). In conclusion, this data indicate a mutational rate of 68% in advanced 
primary colorectal tumours and of 70% in distant hepatic metastases. The data do not 
directly support a prominent role of p53 in late stages of colorectal tumour dissemination. 
However, the primaries analysed in this study were predominantly in advanced tumour 
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stages. Taken together, p53 mutations are frequent events in the progression of colorectal 
cancer and may enhance the development of distant metastases. 
Ann Forslund et al[57] conducted a study in which twenty-nine potentially cured 
patients with colorectal carcinoma, without recurrent disease for more than 6 years after 
their primary surgery, were selected to match a group of 41 colorectal cancer patients 
with early metastatic spread to the liver. All patients were screened for mutations in the 
p53 gene, exons 5 to 9, by denaturing gradient gel electrophoresis and subsequent 
sequencing. The frequency of p53 mutations was significantly different in cured patients 
(60%) compared with patients with early relapse (41%, P < .05). A significant difference 
was found in the distribution of mutations, indicating that potentially cured patients had a 
different proportion of mutations in conserved regions of p53 (P 5 .02). This difference 
was explained by a significantly different frequency of mutations in exon 8 (40% v 15%, 
P 5 .03), which is part of the conserved region V. All mutations in region V were codon 
273 mutations in cured patients, whereas three of four mutations were located in codon 
273 in patients with metastatic disease. Allelic loss of p53 (loss of heterozygosity [LOH]) 
was demonstrated in 26% of the cured patients and in 39% of patients with metastatic 
disease. The combination of mutation and LOH of p53 was the same (17%) in both 
groups. This indicate that a large number of p53 mutations in colorectal cancer do not 
promote disease progression. Some mutations, particularly within conserved regions, may 
even counteract negative functional effects of other p53 structural alterations.  
George E. Theodoropoulos et al[58] in his study collected paraffin-embedded 
materials retrospectively from 164 colorectal adenocarinoma (50 rectal) patients. The 
median follow-up was 5 years (range: 1 to 14). EGFR (Epidermal Growth Factor 
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Receptor) and p53 expression were evaluated by immunohistochemistry. Positive p53 
immunostaining and EGFR expression was observed in 63.4% and 43.9% of patients, 
respectively. EGFR and p53 positivity rates were significantly interrelated (p=0.004). No 
significant correlation was found with the examined clinicopathological parameters 
except for advanced T-stage, which demonstrated significant associations with p53 
expression (p=0.004), EGFR expression (p=0.0001) and p53/EGFR co expression 
(p=0.001). Hence the author concluded that overexpression of p53 and EGFR in the 
colorectal cancer patient population is significantly associated with advanced T stage. 
C Hanski et al[ 59] in his study examined human invasive colorectal carcinomas for 
the overexpression of p53 oncoprotein with the avidin-biotin complex-peroxidase 
staining procedure which detects p53 protein in paraffin-embedded material. The tumours 
were categorized as mucinous (22 cases), most of which originated from adenomas, and 
nonmucinous, which were subdivided into carcinomas originating from adenoma-
carcinoma sequence (ACS) (29 cases) and de novo (DN) carcinomas (25 cases). Nineteen 
DN carcinomas (76%), 21 ACS carcinomas (72%), and 8 mucinous carcinomas (36%) 
exhibited detectable amounts of p53 protein in the tumour cell nuclei. Strong 
overexpression of p53 protein coincided with a high percentage 40%) of stained nuclei in 
40% of ACS and 48% of DN carcinomas versus 9% of mucinous tumours. The 
percentage of stained nuclei, intensity of staining, and distribution of the stained areas did 
not correlate with the grade or the invasive edge of the tumours. These data indicate that 
mucinous carcinomas differ from non-mucinous colorectal carcinomas in their genetic 
lesions. 
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Satoshi Ikeda et al[60]  analysed 813 samples from patients with colorectal non-
mucinous adenocarcinoma (NMC) and 41 samples from those with colorectal mucinous 
adenocarcinomas (MC) over a period of 19 years for p53 expression and beta-catenin 
expression by immunohistochemistry. The overall survival rates of the 41 patients with 
colorectal MC and the 813 patients with colorectal NMC were compared by Kaplan-
Meier survival analysis. The overall 5-year survival rate of patients with colorectal MC 
was 43.1%, and that of patients with colorectal NMC was 79.4% (P = 0.0001 ). The 
frequency of alterations in p53 in colorectal MC was lower than that in NMC, (31.6% 
and 63.6%, respectively) suggesting that the mucinous type occurs through a different 
pathway from that through which NMC occurs.  
Thus from the above studies it is understood that the value of p53 overexpression 
as a prognostic marker in colorectal adenocarcinoma is controversial even though most of 
the studies show poor prognosis in patients with overexpression of p53. Possible causes 
for such discrepancy include differences in study methods, types of mutations analysed, 
laboratory techniques, variable duration of follow-up, statistical differences in study 
power, and heterogeneity in study populations. 
  P53 mutation is a late event in the adenoma-carcinoma sequence in colorectal 
carcinogenesis. It is seen in 70% to 80% of colorectal adenocarcinomas[1]. There is a 
strong correlation between the p53 expression and the stage of the tumour as evidenced 
by the above studies but the correlation with histological grading has not been clearly 
defined.  
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In this study the expression of p53 in varying stages and histological grades of 
colorectal adenocarcinomas in colectomy specimens at the Department of Pathology, 
Stanley medical college has been studied. The results of this study were then compared 
with the above studies.  
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IMMUNOHISTOCHEMISTRY 
 Immunohistochemistry involves two disciplines – immunology and histology. 
Immunohistochemistry is used to determine expression of particular antigen and its 
microanatomic location in the tissue. IHC uses antibodies to distinguish the antigenic 
differences between the cells. These differences can specifically identify the lineage of 
cell population and define biologically distinct populations of cells within the same 
lineage. 
 Immunohistochemistry started in 1940 when Coons developed an 
immunofluorescence technique to detect corresponding antigen in frozen sections. 
 Taylor and colleagues in 1974 showed it was possible to demonstrate antigens in 
routinely processed tissues. Antigen retrieval technique was introduced by Shi and 
associates in 1991. Antigen retrieval technique is a simple method that involves heating 
paraffin processed sections at high temperature before IHC staining. 
 The use of antibody in IHC depends on the sensitivity and specificity of the 
antigen – antibody reaction and the hybridoma technique provides limitless source of 
highly specific antibodies. 
BLOCKING NON – SPECIFIC BACKGROUND STAINING 
 Background staining is due to either non specific binding or presence of 
endogenous enzymes. Non specific binding with polyclonal primary antibody is 
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minimized by pre incubating sections with serum from same species on optimal working 
dilution. 
 Endogenous enzymes such as peroxidase seen in normal and neoplastic tissues is 
abolished by peroxidase blocking or by using alternate systems such as immunogold 
technique. 
 Methods suggested to overcome endogenous peroxidase activity include 
incubation in methanol containing 0.5% hydrogen peroxide for 10 minutes at room 
temperature (almost complete abolition of endogenous peroxidase activity). Endogenous 
alkaline phosphatase is blocked by addition of 0.1 M concentration of levamisole to the 
enzyme substrate solution. 
DETECTION SYSTEMS 
 Antibodies are labeled or flagged by some method to permit visualization – these 
include fluorescent substances, enzymes forming colored reaction with suitable substrate 
(light microscopy) or heavy metals (electron microscopy). 
METHODS OF IHC  
DIRECT LABELING METHOD 
 Antibody is attached with a label by chemical means and directly applied to tissue 
sections. It is a rapid and easy procedure and carries the disadvantage of multiple 
antigens which require separate incubation with respective antibodies. 
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INDIRECT LABELING METHOD 
 Enzymes  are labeled with the secondary antibody, which is produced against the 
primary antibody. This method is more sensitive and easy to handle. The advantages also 
include increased versatility, higher working dilution of primary antibody, secondary 
antibodies against primary antibodies of different species and ease of preparation. 
AVIDIN BIOTIN TECHNIQUES 
 High affinity binding between biotin and avidin is used in this procedure. Biotin is 
chemically linked to primary antibody and avidin is conjugated chemically to enzyme. 
The avidin binds to biotinylated antibody thus localizing the peroxidase moiety at the site 
of antigen.  
 Disadvantages of this technique are that the endogenous biotin produces non 
specific background staining.  
AVIDIN BIOTIN CONJUGATE PROCEDURE 
 In this technique primary antibody is added followed by biotinylated secondary 
antibody and next by preformed complexes of avidin and biotin horse raddish peroxidase 
conjugate. This is a more sensitive method. 
BIOTIN STREPTAVIDIN SYSTEM 
 Streptavidin is used in place of avidin. Streptavidin complexes are more stable. 
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IMMUNOGOLD SILVER STAINING TECHNIQUE 
 This is used in ultrastuctural immunolocalisation. Gold particles are enhanced by 
the addition of several layers of metallic silver. The fine silver deposits in the background 
create confusion when small amounts of antigen are identified.  
POLYMERIC METHOD 
 This technique permits binding of large number of enzyme molecules to a 
secondary antibody via the dextran backbone. Advantages of this technique are increased 
sensitivity, minimized non specific background staining and a reduction in the total 
number of assay steps.  
TISSUE FIXATION, PROCESSING AND ANTIGEN RETRIEVAL 
TECHNIQUES 
 Tissues for IHC undergo fixation, dehydration and paraffin embedding.  
FIXATION 
 This is a critical step as the preservation of morphology is essential for 
interpretation of IHC. 10% buffered neutral formalin is commonly used because of the 
following advantages. 
1. Good morphological preservation 
2. Cheap 
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3. Sterilizes tissues  
4. Carbohydrate antigens are better preserved. 
 The disadvantage of masking of antigens during fixation can be overcome by 
antigen retrieval techniques. 
ANTIGEN RETRIEVAL 
 This procedure involves unmasking of the antigens. Following techniques can be 
used. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval  
3. Microwave and trypsin antigen retrieval technique 
4. Pressure cooker antigen retrieval 
 
 
 
 
 
 
    
 
 
 
 
 
 
MATERIALS  
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MATERIALS AND METHODS 
STUDY DESIGN: -      Longitudinal retrospective study 
TIME PERIOD: -        July 2009 to August 2011.  
SETTING: -                  Department of Pathology, Stanley  medical college, Chennai. 
SAMPLE: -                   A total of 120 colectomy specimens received from the 
departments of General Surgery and Surgical Gastroenterology. 
PLAN 
The patients who were included in this study were screened with predetermined 
inclusion and exclusion criteria. Selected patients underwent through consent protocols. 
Brief clinical history and examination findings were collected with predetermined 
proforma. 
INCLUSION CRITERIA 
 All cases proved to be adenocarcinomas of colorectal region by histopathology 
irrespective of age and sex were included for the study. 
EXCLUSION CRITERIA 
 All malignancies of the colorectal region other than adenocarcinomas and those 
cases with poor clinical data were excluded from the study. 
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METHOD OF DATA COLLECTION 
  All the cases enrolled in the study according to the above criteria were evaluated. 
Of the 120 cases, adenocarcinomas found in 115 cases. Among the 115 cases 100 cases 
had adequate clinical and investigatory data. Clinical history and colonoscopy findings 
were tabulated. Adequate samples were taken from the growths in these specimens. 
  The tissues so obtained were processed and sections were cut at 5 microns. 
Hematoxylin and eosin staining of the sections were done and histopathological 
appearance and extent of the malignancies were studied. Necessary microphotographs 
were taken. 
  The adenocarcinomas found have been categorized into well differentiated, 
moderately differentiated and poorly differentiated based on the amount of glandular 
architecture. The number of cases in each category was tabulated. 
 The staging of the malignancy was done according to the TNM staging system 
and the results were tabulated. 
 Immunohistochemical study of p53 expression was done in 50 cases and the 
degree of p53 expression was scored in each case using the percentage of cells showing 
p53 positivity. The p53 score was correlated with the TNM stage and histological grade 
of the colorectal adenocarcinomas. The results were tabulated and conclusion was drawn. 
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METHODS OF TISSUE PREPARATION FOR IHC 
 Ten percent buffered formalin was used for fixing the specimens, the tissues were 
processed in various grades of alcohol and xylene using automated histokinette. Paraffin 
blocks were prepared and sections of 5 microns thickness were cut in semiautomatic 
microtome using disposable blades and stained with hematoxylin and eosin. Suitable 
blocks were chosen for IHC. 
Sections for immunohistochemistry were also cut in semiautomatic microtome 
using disposable blades. Slides were subjected to antigen retrieval using the microwave 
technique using TRIS EDTA (pH 9.2) buffer solution and then treated by HRP (Horse 
radish peroxidase) polymer technique. 
HRP POLYMER TECHNIQUE 
The coated slides were taken through the following stages  
1. Treatment with peroxidase block – for inhibiting endogenous peroxidase in the 
tissue for 20 minutes. 
2. Wash in TRIS buffer for 5 minutes. 
3. Application of power block – blocks non specific antigen antibody reaction – 20 
minutes. 
4. Blot dry the excess power block. 
5. Application of primary antibody for 60 minutes. 
6. Wash in TRIS buffer for 5 minutes thrice. 
7. Application of super enhancer for 30 minutes which enhances the final reaction 
product by increasing the sensitivity of antigen antibody reaction. 
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8. Application of SS label – secondary antibody from goat with the tagged horse 
radish peroxidase enzyme for 30 minutes. 
9. Wash thrice in TRIS buffer. 
10. Application of DAB (Diamino benzidine) chromogen for 5 minutes – this is 
cleaved by the enzyme to give the coloured product at the antigen sites. 
11. Wash in distilled water for 5 minutes. 
12. The slides are counterstained with hematoxylin. 
13. Air dried and mounted with DPX (Distrene dibutyl pthalide in xylol). 
P53 nuclear staining intensity ranged from strong to moderate to weak. Extent of 
staining varied from multiple positive foci to scattered or rare foci. 
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METHOD OF SCORING FOR p53 
          
 
 
 
 
 
 
Nuclear p53 positivity was defined as staining of the nucleus, irrespective 
of the percentage of positive cells. 
 
 
 
 
 
 
 
SCORE 
 
% OF POSITIVE TUMOUR CELLS  
 
0 
 
1 
 
2 
 
3 
 
 
0% 
 
1% - 10% 
 
11% - 25% 
 
>25% 
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AND  
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OBSERVATION AND RESULTS 
 A total of 100 cases were studied. Histopathological examination and TNM 
staging was done which showed the following results. 
          ADENOCARCINOMAS     -     100 
STAGE 
 I       -     32 
 II       -     25 
 III       -     18 
 IV       -     25 
GRADE 
 I (Figure : 1)      -     41 
 II (Figure : 2)      -     32 
 III (Figure : 3)      -     20 
 Mucinous carcinoma (Figure : 4)              -     07 
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AGE AND SEX DISTRIBUTION OF PATIENTS WITH COLORECTAL 
ADENOCARCINOMAS IN RELATION TO STAGE 
TABLE NO 1 
AGE STAGE I STAGE II STAGE III STAGE IV TOTAL 
 M F T M F T M F T M F T M F T 
21 TO 30 0 0 0 1 0 1 0 1 1 0 0 0 1 1 2 
31 TO 40 6 2 8 2 0 2 2 0 2 1 1 2 11 3 14 
41 TO 50 7 3 10 4 2 6 2 1 3 6 2 8 19 8 27 
51 TO 60 3 2 5 5 2 7 2 2 4 2 1 3 12 7 19 
61 TO 70 4 3 7 2 4 6 3 2 5 5 2 7 14 11 25 
71 TO 80 0 2 2 1 2 3  3 0 3 4 1 5 8 5 13 
TOTAL 20 12 32 15 10 25 12 6 18 18 7 25 65 35 100 
 
Age of patients with colorectal adenocarcinoma was ranging from 24 to 78 years 
and it was more common in males. Stages I & II were categorized as low stage and stages 
III & IV were categorized as high stage. High stage tumours were common in males. In 
those above 60 years of age high stage tumors were common. 
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AGE AND SEX DISTRIBUTION OF PATIENTS WITH COLORECTAL 
ADENOCARCINOMAS IN RELATION TO HISTOLOGICAL GRADE 
TABLE NO 2 
AGE GRADE I GRADE II GRADE III 
MUCINOUS 
CARCINOMA 
TOTAL 
 M F T M F T M F T M F T M F T 
21 TO 30 1 0 1 0 0 0 0 0 0 0 1 1 1 1 2 
31 TO 40 8 2 10 1 0 1 2 0 2 0 1 1 11 3 14 
41 TO 50 11 3 14 6 4 10 0 1 1 2 0 2 19 8 27 
51 TO 60 3 2 5 5 4 9 4 0 4 0 1 1 12 7 19 
61 TO 70 5 1 6 5 7  12 3 2 5 1 1 2 14 11 25 
71 TO 80 1 4 5 0 0 0  7 1 8 0 0 0 8 5 13 
TOTAL 29 12 41 17 15 32 16 4 20 3 4 7 65 35 100 
 
Grade I & II tumours were categorized as low grade and grade III & mucinous 
carcinomas were categorized as high grade. In this study low grade tumours 
predominated in both the sexes and the high grade tumours were more common in males. 
Mucinous carcinomas showed slight female preponderance. However the statistical 
analysis using Chi-Square test revealed no significant correlation (P value = 0.247) 
between sex and the grade/histological type of the tumour.  
    
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
   41 
 
CLINICAL PRESENTATION OF COLORECTAL ADENOCARCINOMAS 
TABLE NO  3 
 
SYMPTOMS 
NO OF 
CASES % 
BLEEDING PER RECTUM 52 52% 
ABDOMINAL PAIN 25 25% 
CONSTIPATION 19 19% 
INTERMITTENT CONSTIPATION 
& LOOSE STOOLS 18 18% 
LOSS OF WEIGHT 15 15% 
INTESTINAL OBSTRUCTION 8 8% 
MUCOUS DIARRHOEA 2 2% 
 
Most common presenting symptoms of colorectal adenocarcinomas were bleeding 
per rectum and altered bowel habits. 
 
 
 
 
    
 
 
 
 
 
BPR – Bleeding per rectum 
ABP – Abdominal pain 
CON – Constipation 
ICL – Intermittent constipation and loose stools 
LOW – Loss of weight 
INT OBS – Intestinal obstruction 
MUD – Mucus diarrhoea 
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COLONOSCOPIC  FINDINGS 
COLORECTAL ADENOCARCINOMA 
TABLE NO 4 
COLONOSCOPIC 
FINDINGS NO OF CASES 
ULCEROPROLIFERATIVE 
GROWTH 78 
POLYP 14 
NARROWING OF LUMEN 8 
TOTAL 100 
 
Most of the colorectal adenocarcinomas exhibited an ulceroproliferative growth 
pattern grossly. 
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SITE DISTRIBUTION OF COLORECTAL ADENOCARCINOMAS 
TABLE NO  5 
 
 
 
 
 
 
 
 
 
 
 
Rectum was the commonest site for colorectal adenocarcinomas (Figures 20 and 21).  
 
 
 
SITE NO OF CASES 
CAECUM 18 
ASCENDING COLON 14 
TRANSVERSE 
COLON 
6 
DESCENDING 
COLON 
4 
SIGMOID COLON 14 
RECTUM 44 
TOTAL 100 
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SITE DISTRIBUTION OF COLORECTAL ADENOCARCINOMAS IN 
RELATION TO SEX  
TABLE NO 6 
SITE MALE  FEMALE TOTAL 
CAECUM 10 8 18 
ASCENDING COLON 10 4 14 
TRANSVERSE COLON 4 2 6 
DESCENDING COLON 2 2 4 
SIGMOID COLON 8 6 14 
RECTUM 31 13 44 
TOTAL 65 35 100 
 
         Rectum was the commonest site of occurrence of colorectal adenocarcinoma in both 
the sexes. 
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SITE DISTRIBUTION OF COLORECTAL ADENOCARCINOMAS IN 
RELATION TO AGE 
TABLE NO 7 
 
SITE 
 
21-30 
 
31-40 
 
41-50 
 
51-60 
 
61-70 
 
71-80 
 
TOTAL 
 
CAECUM 
 
1 
 
1 
 
5 
 
3 
 
5 
 
3 
 
18 
ASCENDING 
COLON 
 
0 
 
4 
 
4 
 
      2    
 
3 
 
1 
 
14 
TRANSVERSE 
COLON 
 
0 
 
1 
 
1 
 
1 
 
2 
 
1 
 
6 
DESCENDING  
COLON 
 
0 
 
0 
 
1 
 
2 
 
0 
 
1 
 
4 
 
SIGMOID 
COLON 
 
0 
 
2 
 
5 
 
1 
 
5 
 
1 
 
14 
 
RECTUM 
 
1 
 
6 
 
11 
 
10 
 
10 
 
6 
 
44 
 
TOTAL 
 
2 
 
14 
 
27 
 
19 
 
25 
 
13 
 
100 
 
In all the age groups the rectosigmoidal region was the commonest site for 
adenocarcinomas. 
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SIZE DISTRIBUTION IN COLORECTAL ADENOCARCINOMAS 
TABLE NO  8 
 
 
 
 
 
 
 
Size of the tumours was ranging from 3 to 13 cm in maximum dimension. Smaller 
tumours were commonly observed probably due to early diagnosis because of increasing 
awareness and utilization of medical services. 
 
 
 
 
 
 
SIZE NO OF CASES 
UPTO 5 CM 62 
6-10 CM 32 
>10 CM 6 
TOTAL 100 
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SIZE DISTRIBUTION OF COLORECTAL ADENOCARCINOMAS IN 
RELATION TO SITE 
TABLE NO  9 
 
SITE 
SIZE  
TOTAL UPTO 5 CM 6-10 CM >10 CM 
CAECUM 10 4 4 18 
ASCENDING COLON 6 6 2 14 
TRANSVERSE COLON 6 0 0 6 
DESCENDING COLON 2 2 0 4 
SIGMOID COLON 8 6 0 14 
RECTUM 30 14 0 44 
TOTAL 62 32 6 100 
 
Larger tumours(>10 cm) were seen commonly in caecum probably due to the 
larger luminal diameter and late presentation. 
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 P53 EXPRESSION IN COLORECTAL ADENOCARCINOMAS 
TABLE NO  10 
S.NO BIOPSY NO. HISTOLOGICAL GRADE STAGE 
(AJCC) 
P53 SCORE 
1 3044/09 III III 3 
2 3164/09 III III 2 
3 3241/09 MUCINOUS CARCINOMA III 0 
4 3470/09 I I 1 
5 3900/09 I I 0 
6 4255/09 III III 2 
7 4422/09 I IV 2 
8 4464/09 I III 2 
9 4500/09 I I 1 
10 4501/09 I I 0 
11 4615/09 II IV 2 
12 4616/09 I I 0 
13 4661/09 I I 0 
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14 4828/09 II I 0 
15 4879/09 II IV 3 
16 5127/09 III III 1 
17 5420/09 I IV 3 
18 5553/09 I IV 3 
19 5880/09 I III 2 
20 5960/09 II II 2 
21 6004/09 I I 3 
22 6024/09 MUCINOUS CARCINOMA II 0 
23 6079/09 I I 1 
24 6091/09 I I 1 
25 6129/09 I IV 3 
26 758/10 II II 2 
27 2712/10 II II 1 
28 2735/10 I II 0 
29 3052/10 I IV 3 
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30 3266/10 II II 3 
31 3276/10 I IV 2 
32 3732/10 I IV 3 
33 3844/10 MUCINOUS CARCINOMA II 1 
34 3879/10 III II 2 
35 4009/10 I I 3 
36 4028/10 II II 3 
37 4183/10 I I 2 
38 4337/10 I III 3 
39 4478/10 MUCINOUS CARCINOMA I 0 
40 4510/10 I IV 2 
41 4691/10 MUCINOUS CARCINOMA II 3 
42 4889/10 I IV 2 
43 4938/10 II III 0 
44 5955/10 I IV 2 
45 6010/10 MUCINOUS CARCINOMA III 1 
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46 6115/10 III IV 3 
47 105/11 III IV 3 
48 199/11 II III 3 
49 630/11 III II 0 
50 839/11 III IV 3 
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 P53 EXPRESSION IN COLORECTAL ADENOCARCINOMAS 
TABLE NO 11 
P53 EXPRESSION POSITIVE NEGATIVE TOTAL 
CONVENTIONAL  
ADENOCARCINOMAS 
36 8 44 
MUCINOUS  
CARCINOMAS 
3 3 6 
TOTAL 39 11 50 
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P53 EXPRESSION IN RELATION TO HISTOLOGY 
TABLE NO 12 
 
ADENOCARCINOMAS 
 
P53 SCORE 
 
TOTAL 
 
0 
 
1 
 
2 
 
3 
CONVENTIONAL 
ADENOCARCINOMAS 
 
8 
 
6 
 
14 
 
16 
 
44 
MUCINOUS 
ADENOCARCINOMAS 
 
3 
 
2 
 
0 
 
1 
 
6 
 
TOTAL 
 
11 
 
8 
 
14 
 
17 
 
50 
 
In this study 78% of the colorectal adenocarcinomas revealed p53 positivity. The 
mucinous carcinomas showed a lower p53 score but the P value for this finding was 
0.101 which is not statistically significant. This may be due to the smaller sample size. 
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P53 EXPRESSION IN CONVENTIONAL ADENOCARCINOMAS IN RELATION 
TO STAGE ( AJCC ) 
TABLE NO 13 
 
STAGE 
(AJCC) 
P53 SCORE TOTAL % 
0 1 2 3 
I 5 4 1 2 12 27.27% 
II 2 1 3 2 8 18.18% 
III 1 1 4 3 9 20.45% 
IV 0 0 6 9 15 34.1% 
TOTAL 8 6 14 16 44 100% 
 
There is progressive increase in p53 score as the stage increases. Statistical 
analysis using Chi-Square test was done which revealed a P value of 0.027 which is 
statistically significant. 
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P53 EXPRESSION IN MUCINOUS CARCINOMAS IN RELATION TO STAGE   
( AJCC ) 
      TABLE NO 14 ` 
 
STAGE (AJCC) 
P53 SCORE TOTAL 
0 1 2 3 
I 1 0 0 0 1 
II 1 1 0 1 3 
III 1 1 0 0 2 
IV 0 0 0 0 0 
TOTAL 3 2 0    1 6 
 
Most of the mucinous carcinomas were in low stage and showed lower p53 
scores. P value cannot be determined due to smaller sample size. 
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P53 EXPRESSION IN COLORECTAL ADENOCARCINOMAS IN RELATION 
TO HISTOLOGICAL GRADE 
        TABLE NO 15 
 
            In different grades of the tumour p53 score was ranging from 0 to 3 (Figures 5 to 
19). Grade III tumours commonly had high scores and most mucinous tumours had low 
scores. But among the cases with high scores grade I & II tumours have predominated  
( 70.6% ). P value was 0.821 which is not significant statistically 
 
 
 
HISTOLOGICAL GRADE 
P53 SCORE TOTAL % 
0 1 2 3 
I 5 4 8 8 25 50% 
II 2 1 3 4 10 20% 
III 1 1 3 4 9 18% 
MUCINOUS CARCINOMA 3 2 0 1 6 12% 
TOTAL 11 8 14 17 50 100% 
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P53 EXPRESSION IN CONVENTIONAL ADENOCARCINOMAS IN RELATION 
TO THE SITE OF THE TUMOUR 
           TABLE NO 16 
SITE 0 1 2 3 TOTAL % 
CAECUM 2 2 2 4 10 20% 
ASCENDING COLON 2 4 2 0 8 16% 
TRANSVERSE COLON 1 0 2 1 4 8% 
DESCENDING COLON 0 0 1 1 2 4% 
SIGMOID COLON 1 0 1 1 3 6% 
RECTUM 5 2 6 10 23 46% 
TOTAL 11 8 14 17 50 100% 
  
            High p53 scores were obtained predominantly in left sided tumours. However 
statistical analysis did not prove this association (P value = 0.541). 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 1  Well differentiated adenocarcinoma – 10X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 2 Moderately differentiated adenocarcinoma – 10X 
     
 
 
 
 
 
  
 
 
 
 
Figure : 3 Poorly differentiated adenocarcinoma – 40X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 4 Mucinous adenocarcinoma – 10X 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 5 Well differentiated adenocarcinoma – p53 Score  0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 6  Well differentiated adenocarcinoma – p53 Score 1 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 7 Well differentiated adenocarcinoma – p53 Score  2 
 
 
 
     Figure : 8 Well differentiated adenocarcinoma – p53 Score 3 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 9 Moderately differentiated adenocarcinoma – p53 Score 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 10 Moderately differentiated adenocarcinoma – p53 Score 1 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 11 Moderately differentiated adenocarcinoma – p53 Score 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 12 Moderately differentiated adenocarcinoma – p53 Score 3 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 13 Poorly differentiated adenocarcinoma – p53 Score 0 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 14 Poorly differentiated adenocarcinoma – p53 Score 1 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure : 15 Poorly differentiated adenocarcinoma – p53 Score 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure : 16 Poorly differentiated adenocarcinoma – p53 Score 3 
     
 
 
Figure : 17 Mucinous adenocarcinoma – p53 Score 0 
 
 
 
                         
 
 
 
 
 
 
 
 
Figure : 18 Mucinous adenocarcinoma – p53 Score 1 
 
     
 
 
 
Figure : 19 Mucinous adenocarcinoma – p53 Score 3 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 20 Abdomino perineal resection – Ulceroproliferative growth in the rectum 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 21 Low anterior resection – Mucinous tumour in the rectum 
4028/10 
4478/10 
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DISCUSSION 
Colorectal carcinoma is by far the most common and most curable cancer of the 
gastrointestinal tract. More than ninety percent of the cancers of the colorectal region are 
adenocarcinomas. Males are affected more often than females. The incidence peaks at 60 
to 70 years of age and fewer than 20% cases occur before 50 years of age[1]. In this study 
the age group for colorectal carcinoma was ranging from 24 to 78 years and  peak 
incidence was at 40 to 70 years with a male preponderance.  
Rectal carcinomas are more common in Asians[1]. In this study rectum was the 
commonest site for colorectal adenocarcinoma in all the age groups. Right sided lesions 
are more likely to present at an older age than distal lesions[1,22]. This is likely due to the 
fact that right sided carcinomas have a greater chance of being asymptomatic and left 
sided lesions on the other hand have a greater chance of presenting with bleeding per 
rectum and changes in bowel habits[1,20] which were the commonest clinical presentation 
in this study also (52% and 39% respectively). Thus these patients are more apt to 
recognize a change in their health and seek medical care earlier. These facts are the 
presumed reasons for presentation of right sided lesions at a later age and advancing stage 
thus having worse prognosis[17]. In accordance with this fact the present study revealed 
high frequency of occurrence of higher stage tumours in those above 60 years of age 
(52.6%) and right sided adenocarcinomas had high stage commonly(53%). 37.5% of 
cases with right sided adenocarcinoma were above 60 years of age 
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Common colonoscopic findings in colorectal carcinoma are ulceroproliferative or 
polypoidal lesions[1] and in this study also similar results were obtained with the 
ulceroproliferative morphology being the commonest (78%).  
Tumours in proximal colons show ulceroproliferative configuration and distal 
lesions are annular that produce napkin ring like constrictions and luminal narrowing[1,18]. 
In this study all those tumours which presented as luminal narrowing were present in the 
rectum (n = 8).  
Studies by Soong R et al [50] and Yuan-Tzu Lan et al[54] have shown that tumour size 
is of no prognostic significance. In this study 67% of the larger tumours (>10 cm) were 
situated in the caecum which may be due to more space available and late presentation of 
these tumours.  
In general the degree of gland formation is widely regarded as the most important 
feature in grading. The colorectal carcinoma has been graded as well differentiated (grade 
I), moderately differentiated (grade II) and poorly differentiated (grade III). Grade IV is 
somewhat redundant as a category that shows no histological evidence of differentiation 
and is classified as a separate histological type by the WHO[4].  
Despite the lack of standardization and documented interobserver variation in the 
assessment, the histological grade has been shown repeatedly by multivariate analysis to 
be a stage-independent prognostic factor and it does not have any correlation with age or 
sex[47,50]. In this study also there was no significant correlation of age and sex with 
histological grade of the tumour. 
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 Colorectal mucinous carcinoma is one of the subsets of colorectal 
adenocarcinoma which is defined according to the WHO as an adenocarcinoma in which 
a substantial amount of mucin (>50% of the tumour) is retained within the tumour[4]. The 
5 year survival rate is 43.1% when compared to non mucinous type (79.4%) in stage II 
and stage III[58]. In our study most of the mucinous carcinomas were in low stage but the 
sample size was too low to get a significant correlation. 71% of the mucinous carcinomas 
were located in the right colon. 
 In colorectal carcinogenesis two distinct pathways are involved. APC / beta-
catenin pathway is associated with classical adenoma-carcinoma sequence and p53 
mutation occurs at late stages of tumour progression. Second pathway is microsatellite 
instability pathway in which the tumours often have mucinous differentiation and are 
frequently located in the right colon. Hence the mucinous carcinomas are reported to 
have a lower frequency of p53 mutation.  
In this study 120 colectomy specimens received in the Department of Pathology, 
Stanley medical college during the year 2009 July to 2011 August were examined. 115 
cases were adenocarcinomas and 100 cases which had adequate clinical and investigatory 
data were included in the study. Among these cases 7 cases were of mucinous subtype. 
In 50 randomly selected cases p53 expression was studied by 
immunohistochemistry in various stages and grades of the tumour which included 6 
mucinous carcinomas. The expression of p53 was scored as 0 to 3 according to the 
percentage of cells showing nuclear positivity irrespective of the staining intensity. 
Results were tabulated and analyzed. For the purpose of statistical analysis stages I and II 
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were categorized as low stage and stages III and IV were categorized as high stage. 
Similarly grade III and mucinous carcinomas were classified as high grade and grades I 
and II were classified as low grade.   
  This study has shown p53 positivity in 78% of colorectal adenocarcinomas. 
According to Robbins and cotran[1], 70-80% of colorectal adenocarcinomas show p53 
mutation. Yamaguchi et al[47] found the immunoreactivity for p53 in 61% of colorectal 
carcinomas. George E. Theodoropoulos et al[58] reported  nuclear positivity for p53 in 
63.4% of colorectal adenocarcinomas. These differences may be due to the use of 
different scoring systems and interobserver variability.   
 J Walker et al[23] in his study concluded that the stage is the most accurate 
prognostic factor for survival and recurrence. In this study there was progressive increase 
in the p53 score as the stage increases. This association was proved to be statistically 
significant using Chi-Square test (P value = 0.027). This is in accordance with the study 
by Flamini ET al[53] and Heide ET al[56].  
Also in a recent study by George E. Theodoropoulos[58] it has been found that p53 
is overexpressed in 63.4% of colorectal cancer patient population and is significantly 
associated with advanced stage (P = 0.004).  
The present study revealed a lower rate of p53 positivity in mucinous tumours 
with most of the tumours being negative for p53. Among the positive cases most had a 
score of 1 but significant correlation could not be obtained due to smaller sample size. 
This is in concordance with the study by C.Hanski et al [59] who found that only 36% of 
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mucinous carcinomas have shown p53 positivity by immunohistochemistry but 76% of 
the non-mucinous adenocarcinomas showed p53 positivity suggesting that mucinous 
tumours develop by a different pathway. Satoshi Ikeda et al [60] also has observed  similar 
findings in their study.  
   This study showed no significant association for increasing grade of the tumour 
with the p53 overexpression which correlates well with the results of  the studies by 
Yamaguchi A et al [47], Soong R et al  [50], Yuan-Tzu Lan et al [54] and C.Hanski et al [59]. 
But high scores were found commonly in well to moderately differentiated tumours 
(70.6%) than poorly differentiated tumours (29.4%). This is in concordance with the 
study by Yuan-Tzu Lan et al[54] who found p53 overexpression in 60% of well to 
moderately differentiated versus 40% of poorly differentiated tumours. This may be due 
to the fact that p53 overexpression may be reduced as the cells become less 
differentiated. So p53 can serve as a differentiation marker in colorectal 
adenocarcinomas. 
 P53 nuclear positivity in this study was found commonly in left sided tumours 
(56.4%) with the rectum predominating among them (46.15%). Similar results were 
found in the study by Antonio Russo et al [45] who found p53 expression in 45% of distal 
tumours as against 34% of proximal tumours. Also Yuan-Tzu Lan et al [54]  in his study 
has observed a statistically significant correlation between the p53 overexpression by 
immunohistochemistry and location of the tumor in the rectum.  
 Since p53 expression has shown a significant association with the stage of the 
disease and since the stage is a proven prognostic marker in colorectal adenocarcinomas 
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p53 expression can be used as a prognostic marker to assess the invasiveness and also the 
metastatic potential of these tumours. 
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SUMMARY AND CONCLUSION 
A total of 120 colectomy specimens were received in the Department of 
Pathology, Stanley medical college during the year 2009 July to 2011 August. 100 cases 
of adenocarcinomas diagnosed by hematoxylin and eosin staining of the tissue sections 
which had adequate clinical and investigatory data were included in the study. Among 
these cases 7 were of mucinous subtype.  
The age group for colorectal adenocarcinoma was ranging from 24 to 78 years 
with the peak age group of 40 to 70 years. Males were commonly affected. The most 
common presenting symptoms were bleeding per rectum and altered bowel habits. 
Colonoscopic finding in most of the tumours was ulceroproliferative growth pattern and 
the most common site was rectum. All the cases presenting with narrowing of lumen 
were seen in the rectum.  
 The tumours were graded as well differentiated, moderate differentiated and 
poorly differentiated and staged according to the TNM system. High frequencies of 
tumours in high stage were seen in above 60 years of age group. Higher stage was more 
common in males and in left sided lesion. Right sided adenocarcinomas had high stage 
commonly. High grade tumours were more common in males and in those above 60 years 
of age. Mucinous carcinomas showed slight female preponderance and most of the 
mucinous carcinomas were located in the right colon. 
P53 expression was studied by immunohistochemistry in various stages and 
grades of the tumour in 50 randomly selected cases which included 6 mucinous 
carcinomas. Scores were given for p53 expression ranging from 0 to 3 according to the 
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percentage of cells showing nuclear positivity irrespective of the staining intensity. 78% 
of the tumours showed p53 positivity. Statistically significant correlation was obtained 
for p53 overexpression and advanced stage but not for grade or site of the tumour. Poorly 
differentiated tumours had low expression of p53. Mucinous tumors had lower expression 
of p53 but the sample size was too low to get a definitive correlation. 
To conclude p53 overexpression plays an important role in the progression of 
colorectal cancer since it correlates strongly with the stage of the tumour and might 
therefore represents an useful marker of prognosis. 
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Sl.NO HPE NO AGE SEX BPR 
ALT 
BH LOW SITE SIZE CONFIGURATION HISTOLOGY GRADE STAGE P53 SCORE 
1 2905/09 71 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I III   
2 2972/09 34 M N Y N TRANSVERSE COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I   
3 3008/09 24 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I II   
4 3014/09 38 M Y N Y SIGMOID COLON UPTO 5 CM POLYP ADENOCA I I   
5 3044/09 72 M N Y N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III III 3 
6 3164/09 74 M Y N N DESCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA III III 2 
7 3204/09 68 M N Y N ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA II I   
8 3241/09 27 F Y N Y CAECUM >10 CM ULCEROPROLIFERATIVE MUCINOUS CA   III 0 
9 3384/09 48 F Y N N RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA II II   
10 3470/09 33 F Y N N ASCENDING COLON UPTO 5 CM POLYP ADENOCA I I 1 
11 3508/09 34 M N Y Y SIGMOID COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA I I   
12 3680/09 37 F N N Y RECTUM UPTO 5 CM NARROWING OF LUMEN MUCINOUS CA   I   
13 3841/09 41 F Y N N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I II   
14 3900/09 66 M Y N N TRANSVERSE COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I 0 
15 4086/09 55 M Y N N RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA II II   
16 4123/09 39 M N Y Y RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I   
17 4255/09 61 M N Y N RECTUM UPTO 5 CM POLYP ADENOCA III III 2 
18 4422/09 64 F Y N N CAECUM >10 CM ULCEROPROLIFERATIVE ADENOCA I IV 2 
19 4464/09 66 M Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA I III 2 
20 4500/09 32 M N Y N ASCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I 1 
21 4501/09 65 M Y N N RECTUM UPTO 5 CM POLYP ADENOCA I I 0 
22 4615/09 67 F N Y N TRANSVERSE COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV 2 
23 4616/09 55 F Y N N RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA I I 0 
24 4661/09 35 M N Y N ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA I I 0 
25 4702/09 66 M Y N N RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA II III   
26 4828/09 43 M N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II I 0 
27 4879/09 59 M Y N N DESCENDING COLON UPTO 5 CM POLYP ADENOCA II IV 3 
28 5127/09 51 M N Y N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III III 1 
29 5312/09 49 F Y N N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV   
30 5420/09 41 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I IV 3 
31 5553/09 43 M N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I IV 3 
32 5762/09 55 F N N Y CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV   
33 5880/09 54 M N Y N TRANSVERSE COLON UPTO 5 CM POLYP ADENOCA I III 2 
34 5960/09 68 F Y N N SIGMOID COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA II II 2 
35 6004/09 64 M N Y N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA I I 3 
36 6024/09 67 F N Y N CAECUM 6-10 CM ULCEROPROLIFERATIVE MUCINOUS CA   II 0 
37 6079/09 57 F N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I 1 
38 6091/09 48 M Y N N ASCENDING COLON >10 CM POLYP ADENOCA I I 1 
39 6129/09  45 M Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA I IV 3 
40 58/10 69 F N N Y ASCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II II   
41 301/10 56 M N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II I   
     
 
Sl.NO HPE NO AGE SEX BPR 
ALT 
BH LOW SITE SIZE CONFIGURATION HISTOLOGY GRADE STAGE P53 SCORE 
42 512/10 46 M N Y N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I III   
43 758/10 66 F Y Y N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II II 2 
44 1018/10 58 M N N Y CAECUM >10 CM POLYP ADENOCA III I   
45 1213/10 76 F N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I II   
46 1362/10 68 F Y N N SIGMOID COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA III III   
47 1672/10 49 M N Y N RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA I I   
48 1831/10 59 F Y N N DESCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA II II   
49 1972/10 41 M Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA I III   
50 2212/10 78 F Y N N TRANSVERSE COLON UPTO 5 CM POLYP ADENOCA I I   
51 2416/10 55 F N N Y RECTUM UPTO 5 CM NARROWING OF LUMEN ADENOCA II II   
52 2607/10 33 M N Y N ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA III III   
53 2712/10 39 M N Y N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II II 1 
54 2735/10 46 M Y N N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I II 0 
55 2819/10 34 M Y N N RECTUM UPTO 5 CM POLYP ADENOCA III II   
56 2961/10 46 M Y N N ASCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I   
57 3052/10 37 F N Y N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I IV 3 
58 3106/10 48 M N Y N CAECUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II IV   
59 3266/10 45 M N Y N TRANSVERSE COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II II 3 
60 3276/10 44 F Y N N ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA I IV 2 
61 3314/10 48 M N Y N RECTUM 6-10 CM POLYP ADENOCA II II   
62 3416/10 72 F Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I   
63 3482/10 56 M N Y N SIGMOID COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA III II   
64 3609/10 44 M Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II IV   
65 3732/10 71 F N N Y RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I IV 3 
66 3800/10 45 M N Y N ASCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV   
67 3844/10 44 M Y N N CAECUM >10 CM ULCEROPROLIFERATIVE MUCINOUS CA   II 1 
68 3879/10 58 M N Y N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA III II 2 
69 3901/10 56 M Y N N RECTUM UPTO 5 CM POLYP ADENOCA II II   
70 4009/10 47 M N Y N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I 3 
71 4028/10 59 M N Y N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II II 3 
72 4183/10 56 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I 2 
73 4217/10 49 F N Y N DESCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II III   
74 4308/10 43 M Y N N RECTUM 6-10 CM NARROWING OF LUMEN ADENOCA I I   
75 4337/10 38 M N Y N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I III 3 
76 4478/10 42 M Y N Y RECTUM UPTO 5 CM ULCEROPROLIFERATIVE MUCINOUS CA   I 0 
77 4510/10 36 M N Y N RECTUM 6-10 CM POLYP ADENOCA I IV 2 
78 4691/10 65 M Y N N CAECUM 6-10 CM ULCEROPROLIFERATIVE MUCINOUS CA   II 3 
79 4701/10 69 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II II   
80 4780/10 44 F Y N N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I I   
81 4889/10 57 M N Y N ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA I IV 2 
82 4938/10 66 F Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II III 0 
 
     
 
Sl.NO HPE NO AGE SEX BPR 
ALT 
BH LOW SITE SIZE CONFIGURATION HISTOLOGY GRADE STAGE P53 SCORE 
83 5096/10 69 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III IV   
84 5128/10 62 F N Y N SIGMOID COLON 6-10 CM POLYP ADENOCA II I   
85 5231/10 63 F N Y N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II I   
86 5378/10 75 F Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA III II   
87 5524/10 64 M N Y N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV   
88 5702/10 46 F Y N N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III I   
89 5790/10 64 M N N Y ASCENDING COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA II IV   
90 5804/10 61 F Y N N SIGMOID COLON UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III I   
91 5955/10 68 M Y N N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA I IV 2 
92 6010/10 58 F N N Y ASCENDING COLON 6-10 CM ULCEROPROLIFERATIVE MUCINOUS CA   III 1 
93 6115/10 69 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III IV 3 
94 105/11 72 M Y N N CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III IV 3 
95 199/11 55 F Y N N RECTUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II III 3 
96 512/11 75 M N N Y CAECUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III IV   
97 630/11 76 M Y N N ASCENDING COLON >10 CM ULCEROPROLIFERATIVE ADENOCA III II 0 
98 741/11 71 M Y N N SIGMOID COLON 6-10 CM ULCEROPROLIFERATIVE ADENOCA III IV   
99 839/11 73 M Y N N RECTUM UPTO 5 CM ULCEROPROLIFERATIVE ADENOCA III IV 3 
100 1278/11 42 F N N Y CAECUM 6-10 CM ULCEROPROLIFERATIVE ADENOCA II I   
 
 
HPE –  Histopathological examination 
BPR –  Bleeding per rectum 
ALT BH –  Altered bowel habits 
LOW –  Loss of weight
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IMMUNOHISTOCHEMICAL EVALUATION OF 
COLORECTAL MALIGNANCIES 
A STUDY OF 100 CASES 
 
ABSTRACT 
 
 Colorectal adenocarcinoma is a major cause of mortality and morbidity 
worldwide. Adenocarcinoma accounts for over 90% of the malignant tumours of the 
colorectal region. Adenoma-carcinoma sequence theory is accepted in carcinogenesis of 
colorectal carcinoma. Mutation of p53 occurs at the time of transition from adenoma to 
carcinoma. In this study 100 cases of adenocarcinomas of the colorectal region were 
analysed for varied clinical presentations, colonoscopic findings, site and size 
distribution. In 50 randomly selected cases with various histological grades and TNM 
stages p53 expression was studied by immunohistochemistry which included 6 mucinous 
carcinomas. Scores were given for p53 expression which were ranging from 0 to 3 
according to the percentage of cells showing positivity irrespective of the staining 
intensity. Statistically significant correlation was obtained for p53 overexpression and 
advanced stage but not for histological grade and site of the tumour. Mucinous tumours 
had a lower expression of p53. Since p53 correlates strongly with the stage of the tumour 
it may represent a useful prognostic marker. 
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